

Mitsubishi Chemical Holdings Corporation
Condensed Consolidated Financial Information
for the First Nine Months of the Fiscal Year Ending March 31, 2012



1. Business Results for the First Nine Months of the Fiscal Year ending March 31, 2012
(Business period: April 1, 2011 to December 31, 2011)

Millions of Yen	
The First Nine months of the Current Fiscal Year	The First Nine months of the Previous Fiscal Year
April 1, 2011- December 31, 2011	April 1, 2010 - December 31, 2010

Thousands of U.S. Dollars
The First Nine months of the Current Fiscal Year
April 1, 2011- December 31, 2011

(1) Results of Operations:

	2,357,505	2,379,293
Net sales		
Operating income	124,544	180,765
Income before income taxes and minority interests in consolidated subsidiaries	116,295	162,514
Net income	32,023	80,208
Comprehensive income	46,365	93,271

30,224,423
1,596,718
1,490,962
410,551
594,423

	(Yen)	(U.S. Dollars)
Net income-Basic per share	21.72	57.03
Net income-Diluted per share	20.33	52.57

0.28
0.26

(2) Segment Information:

[Net Sales by Segment]

Electronics Applications	101,419	116,442
Designed Materials	499,220	492,371
Health Care	386,237	390,446
Chemicals	703,934	669,761
Polymers	521,941	549,809
Others	144,754	160,464
Total	2,357,505	2,379,293

1,300,244
6,400,256
4,951,756
9,024,795
6,691,551
1,855,821
30,224,423

[Operating Income (loss) by Segment]

Electronics Applications	(3,469)	2,408
Designed Materials	21,245	29,667
Health Care	66,189	76,229
Chemicals	18,219	38,155
Polymers	26,949	39,460
Others	2,631	1,746
Adjustments	(7,220)	(6,900)
Total	124,544	180,765

(44,474)
272,372
848,577
233,577
345,500
33,731
(92,564)
1,596,718

Millions of Yen	
The First Nine months of the Current Fiscal Year	The Previous Fiscal Year Ended March 31, 2010
December 31, 2011	March 31, 2011

Thousands of U.S. Dollars
The First Nine months of the Current Fiscal Year
December 31, 2011

(3) Financial Position:

Total assets	3,210,936	3,294,014
Inventories	549,077	485,061
Property, plant and equipment	1,035,326	1,088,369
Short-term and long-term debt	1,218,402	1,304,589
Shareholders' equity*	758,488	758,247
Ratio of shareholders' equity to total assets (%)	23.6	23.0

41,165,846
7,039,449
13,273,410
15,620,538
9,724,205

*Represents the sum of total shareholders' equity and total accumulated other comprehensive income.

Millions of Yen	
The First Nine Months of the Current Fiscal Year	The First Nine Months of the Previous Fiscal Year
April 1, 2011- December 31, 2011	April 1, 2010 - December 31, 2010

Thousands of U.S. Dollars
The First Nine Months of the Current Fiscal Year
April 1, 2011- December 31, 2011

(4) Cash Flows:

	Millions of Yen	Millions of Yen	Thousands of U.S. Dollars
Net cash provided by operating activities	109,912	188,583	1,409,128
Net cash (used in) provided by investing activities	(37,560)	(94,553)	(481,538)
Net cash provided by (used in) financing activities	(100,562)	(97,023)	(1,289,256)
Cash and cash equivalents at end of the period	113,041	105,939	1,449,244

(5) Ratio of Net Income to:

		(%)
Shareholders' equity**	4.2	11.1
Total assets**	0.9	2.3
Net sales	1.3	3.3

** Based on the average of the beginning and ending balances of the respective periods.

Notes:

The Company and its domestic consolidated subsidiaries maintain their accounting recorded in Japanese yen. The U.S. dollar amounts are included solely for convenience and have been translated, as a matter of arithmetical computation only, at the rate of 78 yen to US\$1, the approximate exchange rate prevailing in the Tokyo foreign exchange market at the end of December 2011.

2. Revised Forecast for the Current Fiscal Year

	Millions of Yen	Thousands of U.S. Dollars
	April 1, 2011 - March 31, 2012	April 1, 2011 - March 31, 2012
Net sales	3,220,000	41,282,051
Operating income	135,000	1,730,769
Net income	30,000	384,615
	(Yen)	(U.S. dollar)
Net income per share	20.34	0.26

3. Business Performance and Financial Position

(1) Business Performance

Consolidated Performance for the First Nine Months of Fiscal Year Ending March 31, 2012 (fiscal 2011): Nine Months Ended December 31, 2011

Overview of General Performance

In the first nine months of fiscal 2011, the Japanese economy saw progress in rebuilding its supply chain and showed a gradual trend toward recovery before autumn, under the continuing effects of the Great East Japan Earthquake. Nevertheless, the nation's economy turned to be severe again after autumn due to a downward trend in overseas economies induced by Europe's sovereign debt crisis and the unmitigated appreciation of the yen .

Regarding business environment in the Mitsubishi Chemical Holdings Group, extremely severe environment continued in the Performance Products and Industrial Materials domains due to the effects of the Great East Japan Earthquake, a long-term appreciation of the yen, and a sharp decline in overseas demand. On the other hand, environment in the Health Care domain was generally favorable due to steady performance of demand amid ongoing trend of medical spending constraint despite the influence of the earthquake.

Under the circumstances, the consolidated results for the first nine months of fiscal 2011 were as follows. Net sales slightly decreased by ¥21.8 billion, or 0.9%, to ¥2,357.5 billion compared to the same period of fiscal 2010. Operating income decreased by ¥56.3 billion, or 31.1%, to ¥124.5 billion compared to the same period of fiscal 2010. Ordinary income decreased by ¥55.8 billion, or 31.3%, to ¥122.5 billion compared to the same period of fiscal 2010. Net income decreased by ¥48.2 billion, or 60.1%, to ¥32.0 billion compared to the same period of fiscal 2010. In addition to the above-mentioned effects, net income was inversely affected by tax expenses-deferred recorded in the third quarter of fiscal 2011, as a result of partial reversal of deferred tax assets and liabilities pursuant to the promulgation of the 2011 Reform Amendment Tax Law and the Special Restoration Tax Law.

(2) Overview of Business Segments

Note: In the following section, all comparisons are with the same period of the previous fiscal year unless stated otherwise.

Electronics Applications Segment, Performance Products Domain

(Recording media, Information and electronics-related materials, Imaging supplies)

Net sales in this segment decreased by ¥15.0 billion, or 12.9%, to ¥101.4 billion. Operating income decreased by ¥5.8 billion, and posted a loss of ¥3.5 billion.

In recording media, net sales drastically decreased due to lower sales volumes in DVDs and external hard disk drives and lowering prices, despite increased sales volumes of flash memory devices. In information and electronics-related materials, net sales decreased due to a decrease in sales volumes in display materials. In imaging supplies, net sales decreased due to the appreciation of the yen, despite steady sales performance in OPC drums, toners and chemicals toners.

Major initiatives in the Electronics Applications segment during the first nine months of fiscal 2011 included:

- Mitsubishi Chemical Corporation announced that its subsidiary Mitsubishi Kagaku Media Co., Ltd. and Verbatim Group launched sample kits of *VELVE* the world's first color-tunable dimming-type OLED panel in Europe, North America, Japan, and the Asia Pacific, and a light source module would be launched in July. (April)
- Mitsubishi Chemical Corporation and Pioneer Corporation jointly developed an optimized wet process that results in an efficiency of 52 lm/W at 1,000 cd/m² in white emission, and a half-life of 20,000 hours with the initial brightness at 1,000 cd/m². These two performance characteristics are, as far as we know, the best in the world. (May)
- Mitsubishi Kagaku Media Co., Ltd. announced the introduction of four LED bulb products to the Japanese market under the Verbatim brand in July. The bulbs allow selection of brightness from three pre-set levels without using a dimmer. (June)
- Verbatim Americas, LLC, a subsidiary of Mitsubishi Kagaku Media Co., Ltd., which was sued for trademark infringement in Brazil, made a special appeal to the Superior Court of Justice in Brasilia, asking for a judgment on the matter. In June 2011, the Superior Court of Justice in Brasilia made the decision to dismiss the trademark-infringement suit and also to dismiss a suit from the plaintiff to assess the amount of damages, which were unjustifiably awarded by a lower court. (June)

Designed Materials Segment, Performance Products Domain

(Food ingredients, Battery materials, Fine chemicals, Polymer processing products, Composite materials, Inorganic chemicals, Fibers)

Net sales in this segment increased by ¥6.8 billion, or 1.4%, to ¥499.2 billion. Operating income decreased by ¥8.4 billion, or 28.3%, to ¥21.3 billion, due to the major impact of sluggish demand in products related to flat panel displays.

In food ingredients, business remained unchanged due to continued favorable overseas demand, despite a decrease in sales volumes in domestic demand. In battery materials, net sales increased due to an increase in sales volumes including substitute demand caused by the

earthquake, despite lower sales pricing. In fine chemicals, net sales decreased due to a decrease in sales volumes. In polymer processing products, net sales remained unchanged due to a substantial decrease in sales volumes of polyester films and others for flat panel displays, in spite of an increase in sales volumes in engineering plastic products. In composite materials, net sales of industrial materials such as carbon fibers significantly increased due to continued favorable demand. In inorganic chemicals, net sales drastically decreased due to a decrease in sales volumes by the earthquake. In fibers, net sales increased due to an increase in sales volumes.

Major initiatives in the Designed Materials segment during the first nine months of fiscal 2011 included:

- MRC-SGL Precursor Co., Ltd., a joint venture of Mitsubishi Rayon Co., Ltd. and the SGL Group, successfully started commercial production of PAN-based precursor, at Otake Japan, one of Mitsubishi Rayon's main manufacturing sites. (MRC-SGL Precursor plans to expand its capacity to 7,000t/y within three years.) (April)
- Mitsubishi Plastics, Inc. announced an expansion of its production facility for alumina fiber *MAFTEC* at the Sakaide Plant. (Current capacity: 4,800t/y; capacity increase: 800t/y) (April)
- Mitsubishi Rayon Cleansui Co., Ltd., a Mitsubishi Rayon Group company that markets water purification equipment and medical-use water treatment systems, launched sales of *Cleansui* household water purifiers in Australia and New Zealand, through the extensive sales network of Verbatim Corporation, a subsidiary of Mitsubishi Kagaku Media Co., Ltd. that develops, manufactures and markets recording media products, in May. (May)
- Mitsubishi Chemical Corporation and Stella Chemifa Corporation reached an agreement to start studies on business tie-ups, including the establishment of production facilities for electrolytes, main raw materials for electrolytes solution used in lithium-ion batteries in Europe and the US. (June)
- Mitsubishi Rayon Co., Ltd. and its Group company, Nippon Rensui Co., Ltd. concluded a memorandum with Singapore's national water agency, PUB on the joint development of energy-saving water reclamation technology using the membrane bioreactor method. (July)
- Mitsubishi Rayon Co., Ltd. concluded an agreement with Beijing Origin Water Technology Co., Ltd. to establish a joint venture to manufacture and market hollow fiber membrane for industrial water purification and treatment and to market the membrane bio-reactors (MBRs) system in China. (July)
- Mitsubishi Chemical Corporation announced to expand a production facility of sugar ester at its Yokkaichi Plant. (Current capacity of total food emulsifiers including sugar ester: 10,800t/y; capacity increase: 2,000t/y.) (August)
- Mitsubishi Plastics, Inc. resolved to expand a production facility of separators for lithium-ion batteries at its Nagahama Plant. (Current capacity: 12 million m²; capacity increase: 15 million

m².) (August)

- Mitsubishi Chemical Corporation resolved to establish a subsidiary in China to manufacture and market electrolytes solution for lithium-ion batteries. (Capacity: 10,000t/y.) (September)
- The Nippon Synthetic Chemical Industry Co., Ltd., a subsidiary of Mitsubishi Chemical Corporation, launched *ORGA*, an optical sheet that replaces glass, as a new material to replace reinforced glass on smartphones and others. (November)
- Mitsubishi Chemical Corporation resolved to expand a production facility for lithium-ion battery cathode materials in China. (Current capacity: 4,000t/y; capacity increase: 4,000t/y) (December)
- Mitsubishi-Kagaku Foods Corporation, a subsidiary of Mitsubishi Chemical Corporation, announced establishment of a subsidiary in China to produce and market food ingredients using sugar ester. (Capacity: 2,500t/y) (December)
- Mitsubishi Plastics, Inc. announced that Mitsubishi Plastics has developed high-heat resistant separators for lithium-ion batteries and Mitsubishi Chemical Corporation plans to launch them within fiscal 2012. (December)

Health Care Segment, Health Care Domain

(Pharmaceuticals, Diagnostic reagents and instruments, Clinical testing)

Net sales in this segment decreased by ¥4.2 billion, or 1.1%, to ¥386.2 billion. Operating income decreased by ¥10.1 billion, or 13.3 %, to ¥66.1 billion, due partly to an increase in SG & A expenses.

In the pharmaceutical business, net sales decreased due to a temporary increase in orders for the last fiscal year by the influence of the earthquake, which inversely affected orders for the first nine months of fiscal 2011, despite continued favorable sales in *Remicade*, an anti-TNF α monoclonal antibody; *Maintate*, angina pectoris hypertension and arrhythmias; and others, and a newly recorded royalty revenue of FTY720, treatment for multiple sclerosis. In diagnostic reagents and instruments and clinical testing, net sales remained unchanged.

Major initiatives in the Health Care segment during the first nine months of fiscal 2011 included:

- Mitsubishi Tanabe Pharma Corporation that the company obtained approval for additional indication for selective β 1 antagonist, *Maintate* (generic name: JP bisoprolol fumarate) for chronic heart failure resulting from ischemic heart disease or dilated cardiomyopathy. (May)
- Mitsubishi Tanabe Pharma Corporation announced that it has launched anti-allergy agent, bepotastine besilate (product name in Japan: *Talion*) in China and Indonesia through its consolidated subsidiaries, Tianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia, respectively. (May)

- Mitsubishi Tanabe Pharma Corporation and the Japanese Red Cross Society announced that they have reached an agreement to commence discussions about an integration of Benesis Corporation, a subsidiary of Mitsubishi Tanabe Pharma and Japan Red Cross Society's plasma fractionation operations. (June)
- The Asikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd., a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation, received a 10-day suspension order for manufacturing of pharmaceuticals from Tochigi Prefecture because of failure to perform certain quality assurance tests related to the shipping of products. Furthermore, Mitsubishi Tanabe Pharma received a business improvement order from the Minister of Health, Labour and Welfare. (July)
- Mitsubishi Tanabe Pharma Corporation and Mochida Pharmaceutical Co., Ltd. announced that *Lexapro* 10mg, for which Mochida obtained the marketing approval, has been jointly launched. (August)
- Mitsubishi Tanabe Pharma Corporation announced that the company has received approval for a partial change of dosage and usage in Crohn's disease for an anti-human TNF- α monoclonal-antibody, *Remicade* for I.V. Infusion 100. (August)
- Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. jointly launched a human TNF- α monoclonal antibody, *SIMPONI* Subcutaneous Injection 50mg Syringe, for the treatment of rheumatoid arthritis. It was jointly developed by Mitsubishi Tanabe Pharma and Janssen Pharmaceutical, and in July, Janssen Pharmaceutical obtained the manufacturing and marketing license. (September)
- Mitsubishi Tanabe Pharma Corporation announced that the company has received approval for the manufacturing and marketing of *TELAVIC* 250mg Tablet, an antiviral chronic hepatitis C. (September)
- Mitsubishi Tanabe Pharma Corporation announced that the company obtained the manufacturing and marketing approval for *IMUSERA* Capsules 0.5mg for the indication of prevention of relapse and delay of progression of physical disability in multiple sclerosis. (September)

Chemicals Segment, Industrial Materials Domain

(Basic petrochemicals, Chemical derivatives, Synthetic fiber materials, Carbon products)

Net sales in this segment increased by ¥34.2 billion, or 5.1%, to ¥704.0 billion. Operating income decreased by ¥20.0 billion, or 52.4%, to ¥18.2 billion due to the influence of the earthquake, a decrease in demand, and a shrunk price variance between raw material and product.

The production volume of ethylene, a basic raw material of petrochemicals, decreased by 24.8% to 684 thousand tons compared to the same period of fiscal 2010 due primarily to the ethylene

production facilities at the Kashima Plant of Mitsubishi Chemical Corporation that stopped operations in the wake of the earthquake and reduction of production associated with the deterioration in demand in the third quarter of fiscal 2011. In basic petrochemicals and chemical derivatives, net sales drastically decreased due to a significant decrease in sales volumes by the influence of the earthquake and a decrease in demand in the third quarter of fiscal 2011, despite a sales price adjustment along with an increase in raw materials. In synthetic fiber materials, net sales considerably increased due primarily to an upward trend in terephthalic acid market. In carbon products, net sales of blast furnace coke significantly increased due to an increase in coking coal price.

Major initiatives in the Chemicals segment during the first nine months of fiscal 2011 included:

- Mitsubishi Chemical Corporation announced that the Kashima No. 2 ethylene production facility stopped operations in the wake of the earthquake restarted on May 20, and the Kashima No. 1 ethylene production facility stopped in the same way restarted on June 30 after regular maintenance. (May and June)
- Mitsubishi Chemical Corporation entered into an agreement on basic policies to establish a joint venture in South Korea to manufacture and market needle coke with Posco Group and Mitsubishi Corporation (capacity: approximately 60,000t/y). Based on this agreement, Mitsubishi Chemical plans to strengthen stable supply of raw material for its carbon business by receiving raw material, tar from Posco Group. (September)
- Mitsubishi Chemical Corporation, Asahi Glass Co., Ltd., ADEKA Corporation, Kaneka Corporation, and Shin-Etsu Chemical Co., Ltd. announced a basic five-company agreement on the operation of Kashima Chlorine & Alkali Co., Ltd. and Kashima Vinyl Chloride Monomer Co., Ltd. The two companies are jointly owned by the five companies making the agreement. Asahi Glass, ADEKA and Kaneka will withdraw their capital from Kashima Denkai and Kashima PVC Monomer. Mitsubishi Chemical and Shin-Etsu Chemical will continue to own shares in both joint-venture companies, and the companies will be operated as subsidiaries of Shin-Etsu Chemical. (December)

Polymers Segment, Industrial Materials Domain

(Synthetic resins)

Net sales in this segment decreased by ¥27.9 billion, or 5.1%, to ¥521.9 billion. Operating income decreased by ¥12.5 billion, or 31.6%, to ¥27.0 billion due to a shrunk price variance between raw material and product, in addition to the effects mentioned below.

In synthetic resins, net sales decreased. Part of which is attributable to a substantial decrease in sales volumes in acrylic resin caused by a decreased demand in light guiding panel, despite an

increase in sales volumes along with an upward trend in market conditions of MMA monomer. Besides, by the influence of the earthquake and a decrease in demand in the third quarter of fiscal 2011, sale volumes in polyolefin decreased and sales volumes and market conditions in a phenol-polycarbonate chain worsened.

Major initiatives in the Polymers segment during the first nine months of fiscal 2011 included:

- Mitsubishi Chemical Corporation announced establishment of a joint venture with PTT Public Company Limited to accelerate global expansion of *GS Pla*, a biodegradable plastic. (April)
- Mitsubishi Chemical Corporation announced conclusion of an agreement on business partnerships with BioAmber Inc. and Mitsui & Co., Ltd. which has interest in BioAmber. The partnership is to be concentrated on supplying biomass succinic acid, conducting R&D, and production technologies for the biomass biodegradable plastic, *GS Pla*. (April)
- Mitsubishi Chemical Corporation and Genomatica, Inc. concluded an agreement to jointly develop production technologies to produce chemicals such as 1,4-butanediol from biomass resources. (April)
- Mitsubishi Chemical Corporation announced an increase in PVC compound production capacity in Thailand. (Current capacity: 15,000t/y; capacity increase: 4,000t/y) (May)
- Mitsubishi Chemical Corporation announced establishment of a new production facility for olefin thermoplastic elastomer and adhesive polymer in China (capacity: 4,500t/y), and to expand a production facility for olefin thermoplastic elastomer and adhesive polymer in North America (Current capacity: 9,200t/y; capacity increase: 1,900t/y). (May)
- Mitsubishi Rayon Co., Ltd. and Saudi Basic Industries Corporation (SABIC) announced conclusion of an agreement aiming to the formation of a joint venture company to build and operate two plants – one for methyl methacrylate (MMA; capacity: 250,000t/y) and the other for polymethylmethacrylate (PMMA; capacity: 40,000t/y) – at one of SABIC's manufacturing affiliates in Jubail, Saudi Arabia. (May)
- Mitsubishi Rayon Co., Ltd. resolved to launch production of 2-hydroxyethyl methacrylate (2HEMA) (capacity: 11,000t/y) at Daesan MMA Corp. of South Korea, a joint venture set up with Honam Petrochemical Corp. (September)
- Mitsubishi Chemical Corporation announced that Mitsubishi Chemical and A. Shulman, Inc. agreed to dissolve and liquidate their joint venture established by their subsidiaries, THE SUNPRENE CO., which is engaged in vinyl chloride compound business in North America. THE SUNPRENE's business will be transferred to Mitsubishi Chemical Performance Polymers, Inc., a subsidiary of Mitsubishi Chemical. (November)
- Mitsubishi Rayon Co., Ltd. and its subsidiary group, Lucite International, announced that they are continuing their drive to develop alternative sustainable feedstock sources for the production of methyl methacrylate (MMA), using both existing technologies and developing completely new bio-based routes for methacrylate monomers. (November)

Others

(Engineering, Logistics)

Net sales in this segment decreased by ¥15.7 billion, or 9.8%, to ¥144.8 billion. Operating income increased by ¥0.9 billion, or 52.9%, to ¥2.6 billion.

In engineering, the business continued favorably. In logistics, net sales decreased due to the influence of the earthquake. Other than these, net sales in other businesses decreased due primarily to termination of some purchase and resale business.

Group in General

Major initiatives in the Group in general other than the above-mentioned segments during the first nine months of fiscal 2011 included:

- Mitsubishi Chemical Holdings Corporation resolved to relocate the Mitsubishi Chemical Holdings Group headquarters to a new location from May to August 2012. Mitsubishi Chemical Holdings, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Inc., and Mitsubishi Rayon Co., Ltd., which are all in Tokyo, will move to a single headquarters office building and a part of the offices of Mitsubishi Tanabe Pharma Corporation, which is headquartered in Tokyo and Osaka, will move to the new headquarters as well. (August)

4. Consolidated Financial Position

At the end of the first nine months of fiscal 2011, total assets amounted to ¥3,210.9 billion, a decrease of ¥83.1 billion compared to the end of fiscal 2010. This reflected a decrease in tangible fixed assets due primarily to that depreciation exceeded capital expenditures, a decrease in investment securities caused by a decline in market value of shares held, and a decrease in cash and deposits and securities used to reduce interest-bearing debts, while inventories increased.

5. Consolidated Financial Results Forecasts for Fiscal 2011

The consolidated financial results forecasts for fiscal 2011 announced on November 1, 2011 have been revised downward in light of the results of the first nine months of fiscal 2011. This was due primarily to that demand and market conditions for petrochemicals in the third quarter of fiscal 2011 were significantly declined in excess of our expectations.

In addition, net income was inversely affected by tax expenses-deferred recorded in the third quarter of fiscal 2011, as a result of partial reversal of deferred tax assets and liabilities pursuant to the promulgation of the 2011 Reform Amendment Tax Law and the Special Restoration Tax Law.

1) Revised consolidated financial results forecasts for fiscal 2011

(Units are in billions of yen, otherwise noted.)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecasts (A) (announced on November 1, 2011)	3,350.000	200.000	195.000	77.000	52.22 yen
Revised forecasts (B)	3,220.000	135.000	132.000	30.000	20.34 yen
Difference (B-A)	(130.000)	(65.000)	(63.000)	(47.000)	-
Difference (%)	(3.9)	(32.5)	(32.3)	(61.0)	-
Reference: Results for fiscal 2010	3,166.771	226.493	223.899	83.581	58.72 yen

Forward-looking Statements

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond company control. Actual results could differ materially due to numerous factors, including without limitation market conditions, and the effect of industry competition. The company expectations for the forward-looking statements are described in page [2], [10] and [11] hereof.